What this study is
The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:
What form of recruitment communication is most effective for completing a type 1diabetes home screening kit?
Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).
Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.
What's being tested
- phone call
Intervention · BEHAVIORAL
Recruitment through phone call
- email/mail
Intervention · BEHAVIORAL
Recruitment through email and mail
Study details
- Official title
- Finding Immune Nascent Type 1 Diabetes (FIND T1D)
- Sponsor
- Indiana University
- Conditions
- Healthy Adult · Type 1 Diabetes (T1D)
- Enrolling
- 3,800 people
- Starts
- 2026-07-28
- Est. completion
- 2029-06
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 1 Year – 99 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Participant must be in Indiana Biobank
- Participant must be able to provide consent
- Ages 1-99 including pregnant women
You can't join if
- Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study
- While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openIndiana University School of Medicine
Indianapolis, Indiana, United States
- Emily K Sims, MD · Principal investigator
Recruiting
Study team
Sponsor
Indiana University
Study ID 31119
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.